Nina Hoss enters a conversation about “Hedda” the way her character Eileen Lövborg enters that fateful party: She commands ...
6hon MSN
Cidara signals over 100M U.S. patient opportunity as CD388 Phase III trial enrollment expands
Cidara Therapeutics' Q3 2025 call highlights accelerated Phase III CD388 progress, expanded patient reach, FDA breakthrough status, and $339M BARDA funding.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback